487
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

, , , , , , , , , , , , , , & show all
Pages 2089-2100 | Received 05 Sep 2016, Accepted 08 Dec 2016, Published online: 16 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Xiao Liu, Hao Tang, Jing Liu & Xiang Wang. (2020) hsa_circRNA_101237: A Novel Diagnostic and Prognostic Biomarker and Potential Therapeutic Target for Multiple Myeloma. Cancer Management and Research 12, pages 2109-2118.
Read now

Articles from other publishers (9)

Guilin Tang, Yilin Wu, Pei Lin, Gokce A. Toruner, Shimin Hu, Shaoying Li, Muzaffar H. Qazilbash, Robert Z. Orlowski, Christine Ye, Jie Xu, Karen A. Nahmod, L. Jeffrey Medeiros & Zhenya Tang. (2023) Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers 15:23, pages 5690.
Crossref
Ivyna Pau Ni Bong & Ezalia Esa. (2023) Molecular genetic aberrations in the pathogenesis of multiple myeloma. Asian Biomedicine 17:4, pages 152-162.
Crossref
Wen Gao, Yuan Jian, Juan Du, Xiaozhe Li, Huixing Zhou, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Weijun Fu, Juan Li & Wenming Chen. (2020) Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. Cancer Medicine 9:21, pages 7819-7829.
Crossref
Huanping Wang, Haitao Meng, Jinghan Wang, Yinjun Lou, Yile Zhou, Peipei Lin, Fenglin Li, Lin Liu, Huan Xu, Min Yang & Jie Jin. (2019) Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. Frontiers of Medicine 14:3, pages 327-334.
Crossref
Smith Giri, Scott F. Huntington, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff & Natalia Neparidze. (2020) Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 4:10, pages 2245-2253.
Crossref
Heinz Ludwig, Wolfram Poenisch, Stefan Knop, Alexander Egle, Martin Schreder, Daniel Lechner, Roman Hajek, Eberhard Gunsilius, Karl Jochen Krenosz, Andreas Petzer, Katja Weisel, Dietger Niederwieser, Hermann Einsele, Wolfgang Willenbacher, Thomas Melchardt, Richard Greil & Niklas Zojer. (2019) Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer 121:9, pages 751-757.
Crossref
Zihua Guo, Huijun Li, Yudi Geng, Jian Cui, Ning Tang & Dengju Li. (2018) Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. The American Journal of the Medical Sciences 355:4, pages 350-356.
Crossref
M Binder, S V Rajkumar, R P Ketterling, P T Greipp, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, S R Hayman, Y L Hwa, S R Zeldenrust, J A Lust, S J Russell, N Leung, P Kapoor, R S Go, W I Gonsalves, R A Kyle & S K Kumar. (2017) Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer Journal 7:9, pages e600-e600.
Crossref
Nadine K Berry, Amanda Dixon-McIver, Rodney J. Scott, Philip Rowlings & Anoop K Enjeti. (2017) Detection of complex genomic signatures associated with risk in plasma cell disorders. Cancer Genetics.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.